|Kristin Hodous||Senior Manager, IR|
|Mike Landsittel||VP, Finance|
|Terence Flynn||Goldman Sachs|
|Andrew Berens||Leerink Partners|
|Joseph Thorne||Cowen & Company|
|Laura Chico||Raymond James|
|Konstantinos Aprilakis||JMP Securities|
Good day, ladies and gentlemen, and welcome to the Blueprint Medicines Third Quarter 2018 Financial and Operating Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions].
As a reminder, this conference is being recorded.